The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine

The Dose-response Relationship of Rocuronium in Patients Taking Pyridostigmine Preoperatively Compared With Age and Sex Matched Controls

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02157545

Enrollment

Registered

2014-06-06

Start date

2014-03-31

Completion date

2016-05-31

Last updated

2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Relaxants

Keywords

muscle relaxants, pyridostigmine, pharmacodynamics, potency

Brief summary

Pyridostigmine is a medication that is used in certain heart rate and blood pressure conditions. This medication, as a side effect, is known to also cause changes in the junction between a nerve and muscle. The changes caused at the nerve muscle junction by pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery and anesthesia). The investigators are conducting this study to see whether patients taking pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used during surgery).

Detailed description

No subjects enrolled. No data collected.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients who take pyridostigmine for any reason or those who are matched by age, sex and weight to subjects taking pyridostigmine * Patients who will be administered rocuronium during elective procedures as standard clinical care.

Exclusion criteria

* Allergy to rocuronium * Known neuromuscular disorder, patients suffering from myasthenia gravis * Subjects taking medications known to impact neuromuscular transmission (ex. gentamicin).

Design outcomes

Primary

Measure	Time frame	Description
Dose of the muscle relaxant rocuronium that will lead to 50% decrease in the force of the evoked muscle contraction in patients taking pyridostigmine.	12 months	Rocuronium used to produce muscle weakness or paralysis during surgery. Its potency is measured as ED50, the dose necessary to cause a 50% reduction in the force of evoked muscle contraction. We intend to determine this measure of potency (ED50 for rocuronium) in patients taking pyridostigmine and compare it with control subjects.

Countries

United States

Outcome results